Milk Thistle Supplements: Which Form and Dose Actually Get Absorbed, and What the Evidence Shows

Milk thistle is one of the most recommended herbs for liver support and one of the most confidently mis-sold. Two things decide whether a bottle actually helps: the form, which decides how much you absorb, and the label, which decides whether the bottle holds what it claims. The strongest human trials are also less flattering than the marketing suggests, and an honest guide has to start there.

What Milk Thistle Actually Contains

Milk thistle is Silybum marianum, a tall thistle with purple flowers that has been used for liver complaints for centuries, a plant whose chemistry has been reviewed in detail in the botanical literature [10]. The part that goes into a capsule is the seed extract, and the part that does the work is a mixture, not a single compound.

That mixture is called silymarin. It is not one molecule. It is a family of flavonolignans, usually 65 to 80 percent of a standardised extract, made up of silybin A and silybin B, isosilybin A and isosilybin B, silychristin, isosilychristin, silydianin, and the flavonoid taxifolin [8][10].

Within that family, silybin A and silybin B are considered the most biologically active components. They are the two mirror-image forms, in about a 1 to 1 ratio, of a compound called silibinin, and they are what the absorption research focuses on [8][2].

This matters because of what a front label usually does not tell you. A bottle that says "Milk Thistle 1,000 mg" is almost always describing the weight of the raw herb or the extract, not the silymarin inside it. Two bottles can both say 1,000 mg and deliver wildly different amounts of the only fraction that has been studied.

So the first skill in buying milk thistle is learning to read past the front of the bottle to the number that matters, the standardised silymarin.

Why the Form Decides What You Absorb

Silymarin has a delivery problem, and it is the single most useful fact in this article. The compound is poorly soluble in water and, taken as plain extract, is absorbed weakly and heavily broken down on its first pass through the liver [4][2].

Swallow a plain silymarin capsule and only a fraction of what is on the label reaches your bloodstream in a form your body can use.

This is not a marketing problem. It is a pharmacokinetic one, and it has been measured. In a study of nine healthy volunteers, researchers gave a single dose of a silybin and phosphatidylcholine complex, or a plain silymarin dose matched to 360 mg of silybin, and compared the resulting plasma levels. The complex produced much higher plasma silybin at every time point. The researchers concluded that binding silybin to phosphatidylcholine greatly increases its oral bioavailability, probably by helping it cross the gut lining [3].

Two details from that same study are worth remembering. The half-life was short, generally under four hours. And less than 3 percent of the dose reappeared in the urine, with much of it likely excreted in bile [3]. Short half-life is why the trials dosed two to three times a day, and it is why a single morning capsule is not the same plan.

Newer delivery work points the same way. In a 2025 randomised crossover trial in 16 healthy adults, a micellar formulation of silymarin at 130 mg produced roughly 19 times the peak plasma concentration and about 11 times the total exposure of a standard milk thistle product at the same silymarin dose [4]. Different technology, same lesson.

Here is the practical version:

If you remember one buying rule from this article, make it this one: with milk thistle, the delivery form is not a nice-to-have. It is the difference between taking a studied dose and taking a dose your body mostly discards.

What the Human Trials Actually Found

Now the part the marketing skips. Milk thistle has been studied hard, and the strongest trials are, honestly, disappointing.

The National Center for Complementary and Integrative Health, part of the National Institutes of Health, sums up the field this way: there is not enough high-quality evidence to reach definite conclusions about milk thistle's effects on health conditions [1]. That is a careful sentence, and it is not a ringing endorsement.

The two trials behind that caution are worth naming, because they were large, well designed, and funded to answer the question directly.

• The hepatitis C trial (2012, JAMA). Researchers gave 154 people with chronic hepatitis C who had not responded to interferon either 420 mg of silymarin, 700 mg of silymarin, or a placebo, three times a day for 24 weeks. At the end, only two people in each group met the primary liver marker outcome. The authors reported no benefit in either silymarin group [5].
• The fatty liver trial (2019, PLOS ONE). This one tested high-dose silymarin in 78 people with non-alcoholic steatohepatitis over 48 weeks. The proportions reaching the primary endpoint were 15 percent on the higher dose, 19 percent on the lower dose, and 12 percent on placebo, a difference the statistics did not support. The authors found no benefit [6].

An independent herb database reaches the same conclusion from a different direction, noting that in a large chronic hepatitis C study, silymarin did not significantly reduce the liver enzyme ALT [9]. A 2025 scoping review of supplement interventions for metabolic liver disease likewise found the evidence mixed and generally low certainty [13].

So the honest headline is this: in the best-designed trials, high-dose milk thistle did not improve hard liver-disease outcomes. Anyone telling you it heals the liver is selling something the evidence does not carry.

That said, "not proven for disease outcomes" is not the same as "does nothing." Smaller studies have shown signals in narrower, lower-stakes settings. In a 60-person study of allergic rhinitis, silymarin at 140 mg three times a day improved symptom scores when added to antihistamine therapy [11]. Several small trials in type 2 diabetes, mostly in Middle Eastern populations, suggested modest effects on blood sugar, though the NCCIH notes it is unclear whether those results would repeat elsewhere [1]. Milk thistle also appears in supportive care research for mouth and skin side effects of cancer treatment, work that is preliminary [9].

What that adds up to is a herb with real antioxidant activity and an honest ceiling. Supportive, not curative. Worth taking thoughtfully if you want general liver support, not worth believing it will reverse a diagnosis.

The Four Label Checks That Decide Whether It Works

Because the evidence ceiling is low and the label variation is high, the label does most of the work. Four checks take about a minute.

Check one: find the silymarin milligrams, not the milk thistle milligrams

The number that matters is the standardised silymarin amount, stated in milligrams, on the Supplement Facts panel. If a bottle says "Milk Thistle 1,000 mg" and never gives a silymarin figure, you cannot compare it to any study, because the studies measured silymarin, not raw herb.

Check two: look at the standardisation percentage, and its method

A standardised extract states a percentage, usually 80 percent. There is a catch in how that percentage is measured. ConsumerLab, an independent testing group, explains that the older UV-VIS assay reports a higher silymarin percentage than the more specific HPLC method, roughly 80 percent versus 58 percent for the same material [7]. A label that says 80 percent may be measuring generously. It is not dishonest, but it is not the same as a tested number.

Check three: do the serving math

Supplements quote per serving, and a serving is often two capsules, not one. Multiply the silymarin per serving by the servings per container to see the real daily cost, and check how the label's suggested use maps to the studied dose.

Check four: identify the delivery form

Look for a phospholipid or phytosome complex, a micellar or liposomal form, or explicit "complexed for absorption" language. Given how poorly plain silymarin absorbs, this check often matters more than a higher raw milligram count [3][4].

If a label passes all four, you are holding something you can compare, honestly, to the research.

The Label Accuracy Problem

Then there is the problem underneath all of it: the label might not be true.

ConsumerLab tested ten milk thistle supplements from a range of popular brands. The silymarin content ran from 17.4 mg to 647.9 mg per daily serving, a spread of about 3,700 percent. Three of the ten products contained far less silymarin than their labels implied, and were rated not approved for quality [7].

That last finding is the one to sit with. You can do every label check correctly, buy the right form, take the right dose, and still miss, because the number on the panel was not the number in the capsule.

The NCCIH flags the same worry, noting that some milk thistle products have been found to contain silymarin amounts substantially different from what their labels state, or to be contaminated with pesticides, microorganisms, or mycotoxins from moulds [1].

The practical defence is boring and effective: buy from brands that publish a certificate of analysis or submit to third-party testing. It does not prove the dose is effective, but it does answer the more basic question of whether the bottle contains what it claims. Our guide to professional-grade quality standards covers what that testing does and does not tell you.

Dose and Timing That Match the Studies

With the form and the label settled, dosing is straightforward, because the trials converge on a pattern.

The most common studied pattern is a divided daily total, not a single capsule. ConsumerLab notes that most clinical trials used extracts of about 200 mg providing around 116 mg or more of silymarin, taken two to three times a day [7]. That works out to roughly 230 to 350 mg of silymarin across the day, from about 400 to 600 mg of extract.

Other sources agree on the shape. An extract containing 200 to 400 mg per day of silymarin is the historical reference point, and milk thistle has been considered safe at 420 mg per day in divided doses for up to 41 months [8]. The smaller positive studies, like the allergic rhinitis trial, used 140 mg of silymarin three times a day [11], and the two large null trials deliberately pushed higher, to 420 and 700 mg three times a day [5][6].

The short half-life explains the split dosing. With a plasma half-life generally under four hours, one large morning dose is gone by afternoon, and the twice to three times daily pattern in the trials is not arbitrary [3].

On timing, the practical default is to take it with a meal, which is what most of the product labels suggest and what suits a compound that needs help dissolving [8]. Beyond that, morning or night is personal preference, and consistency matters more than the clock. Our guide to reading a supplement label walks through how to map any product's suggested use to a schedule you will actually keep.

Do not expect speed. This is a slow, supportive herb, and the trials that ran were measured in months, not days.

Side Effects, Interactions, and Who Should Be Careful

Milk thistle is generally well tolerated, which is part of why it is so widely used. The most common complaints are digestive and mild: bloating, gas, nausea, a feeling of fullness, and occasional changes in bowel habits [1][8].

Higher doses carry a little more to watch. Doses in the hundreds of milligrams per day have been reported to raise bilirubin and liver enzyme levels, usually without symptoms, and mild allergic reactions have been reported above 1,500 mg per day, though toxic effects have not been noted clinically at 1,200 mg per day [9][8].

Allergy is a real consideration for some people. Milk thistle is in the daisy family, so anyone allergic to ragweed, chrysanthemum, marigold, or daisy should treat it with care [1].

Interactions deserve more attention than they usually get, because milk thistle touches liver enzymes that process many drugs.

• Warfarin. A case report described a man on warfarin whose INR rose from 2.64 to 4.12 after taking a liver cleanse containing milk thistle; it normalised after he stopped the supplement [9].
• Sirolimus. Milk thistle may increase the side effects of this medication, and a health practitioner should be told if you take both [9].
• Drugs processed by UGT enzymes and CYP3A4. Milk thistle modulates these pathways in laboratory work, and silybin and isosilybin inhibit a key induction pathway for CYP3A4 [9].
• General caution. Data on milk thistle's effect on several cytochrome P450 enzymes is mixed, so monitoring is reasonable when it is combined with medications processed by those enzymes [8].

Pregnancy and breastfeeding are usually listed with caution rather than a green light, because the safety data are limited even though traditional use has been common [1][8].

One more nuance worth knowing, because it circulates online: the milk thistle flavonolignan silychristin has been identified in laboratory screening as an inhibitor of a thyroid hormone transporter called MCT8. A follow-up animal study dosed rats with silychristin for a week and found no change in serum thyroid hormone levels [12]. The laboratory flag is real, and the in vivo follow-up did not confirm a hormone effect. If you take thyroid medication, treat it as one more reason to mention milk thistle to your clinician rather than to panic about it.

That is the general rule for this herb: it is gentle, but it is not inert, and if you take prescription medication, a quick check with a professional is worth more than any label. Our guide to medications that affect nutrient status is a useful companion.

What We Recommend

Nothing below replaces the label checks above. These four were chosen on what their own Supplement Facts panels actually disclose, and they map to the two things this article found that matter most: matching the studied dose, and choosing a better-absorbed form. Every product, price, and stock figure was verified live on October 10, 2026.

Whichever you choose, run the four checks on the bottle in your hand before you buy it. That habit will serve you better than any single recommendation, and it is the same discipline behind our digestion and gut health and detox and methylation resources.

References

1. National Center for Complementary and Integrative Health (NCCIH), U.S. National Institutes of Health. "Milk Thistle." https://www.nccih.nih.gov/health/milk-thistle. States that there is not enough high-quality evidence to reach definite conclusions about milk thistle's effects on health conditions; notes that two NIH-funded studies, one in hepatitis C and one in non-alcoholic steatohepatitis, did not show benefit, and flags poor chemical and microbiological quality in some products plus allergy concerns in the daisy and ragweed family. Also reports that small studies suggest possible blood sugar effects in type 2 diabetes, with most of that research done in Middle Eastern countries and unclear whether it would repeat elsewhere, and states that little is known about safety during pregnancy or breastfeeding.
2. Bijak M. "Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.): Chemistry, Bioavailability, and Metabolism." Molecules, 2017. PMID 29125572. DOI 10.3390/molecules22111942. Reviews silybin as the major and most active component of silymarin and documents its poor bioavailability and extensive metabolism.
3. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. "Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects." Eur J Drug Metab Pharmacokinet, 1990. PMID 2088770. DOI 10.1007/bf03190223. In nine healthy volunteers, the silybin-phosphatidylcholine complex produced much higher plasma silybin levels than plain silymarin at an equal 360 mg silybin dose; half-life was generally under 4 hours, under 3 percent of the dose was recovered in urine, and a significant proportion of the dose was probably excreted in bile.
4. Chang C, Zhang Y, Kuo YC, et al. "Novel Micellar Formulation of Silymarin (Milk Thistle) with Enhanced Bioavailability in a Double-Blind, Randomized, Crossover Human Trial." Pharmaceutics, 2025. PMID 40733088. DOI 10.3390/pharmaceutics17070880. In 16 healthy adults, a micellar silymarin formulation at 130 mg silymarin showed about 18.9-fold higher peak concentration and 11.4-fold higher total exposure than a standard product.
5. Fried MW, Navarro VJ, Afdhal N, et al. "Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial." JAMA, 2012. PMID 22797645. DOI 10.1001/jama.2012.8265. In 154 patients given 420 mg or 700 mg of silymarin or placebo three times daily for 24 weeks, only two participants in each group met the primary liver outcome, indicating no benefit.
6. Navarro VJ, Belle SH, D'Amato M, et al. "Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial." PLoS One, 2019. PMID 31536511. DOI 10.1371/journal.pone.0221683. In 78 patients given 420 mg or 700 mg of silymarin or placebo three times daily for up to 48 weeks, 15 percent, 19 percent, and 12 percent respectively reached the primary histological endpoint, a non-significant difference.
7. ConsumerLab.com. "Milk Thistle and Liver Formula Supplements Review." https://www.consumerlab.com/reviews/milk-thistle-and-liver-supplements/milkthistle/. Reported a roughly 3,700 percent difference in silymarin content across ten tested products, ranging from 17.4 mg to 647.9 mg per daily serving, with three products containing far less than their labels implied; notes that UV-VIS testing reports higher silymarin percentages than the more specific HPLC method, and that most clinical trials used extracts of about 200 mg providing 116 mg or more of silymarin, taken two to three times daily.
8. Drugs.com Natural Products Database. "Milk Thistle." https://www.drugs.com/npp/milk-thistle.html. Describes silymarin as a flavonolignan complex of 65 to 80 percent, with silybin A and B the most active components; notes poor oral availability improved by phospholipid complexes; lists a suggested silymarin range of 200 to 400 mg per day and safety at 420 mg per day in divided doses; documents mixed cytochrome P450 interaction data and common gastrointestinal side effects; advises caution in pregnancy and breastfeeding because the available data are limited.
9. Memorial Sloan Kettering Cancer Center. "Milk Thistle." https://www.mskcc.org/cancer-care/integrative-medicine/herbs/milk-thistle. Notes that silymarin did not significantly reduce ALT in a large chronic hepatitis C study; reports that high doses can raise bilirubin and liver enzymes; and lists herb-drug interactions including warfarin (an INR rise from 2.64 to 4.12 in one case), sirolimus, and UGT and CYP3A4 substrates; also surveys early supportive-care research on radiation-induced oral mucositis and chemotherapy-related hand-foot syndrome.
10. Zhang X, Liu M, Wang Z, et al. "A review of the botany, phytochemistry, pharmacology, synthetic biology and comprehensive utilization of Silybum marianum." Front Pharmacol, 2024. PMID 39055491. DOI 10.3389/fphar.2024.1417655. Comprehensive review of milk thistle chemistry and pharmacology, including the silymarin flavonolignan composition.
11. Bakhshaee M, Jabbari F, Hoseini S, et al. "Effect of silymarin in the treatment of allergic rhinitis." Otolaryngol Head Neck Surg, 2011. PMID 21952357. DOI 10.1177/0194599811423504. In 60 patients with allergic rhinitis, silymarin 140 mg three times daily for one month improved clinical symptom severity scores versus control when added to antihistamine therapy.
12. Renko K, Thomas R, Hawks M, et al. "Examining in vivo effects of silychristin, a potent in vitro inhibitor of thyroid hormone transporter MCT8." Front Toxicol, 2026. DOI 10.3389/ftox.2026.1796387. Identifies the milk thistle flavonolignan silychristin as an in vitro inhibitor of the MCT8 thyroid hormone transporter, but found no change in serum thyroid hormone concentrations in rats dosed for seven days.
13. Handu D, Stote K, Piemonte T. "Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review." Nutrients, 2025. PMID 39940310. DOI 10.3390/nu17030453. Scoping review of supplement interventions for metabolic dysfunction-associated steatotic liver disease, finding the evidence mixed and of generally low certainty.
14. Lai JC, Ring M, Dhruva A, Yeh GY. "A patient-centered approach to dietary supplements for patients with chronic liver disease." Hepatol Commun, 2024. PMID 39445862. DOI 10.1097/hc9.0000000000000552. Discusses how to counsel patients with chronic liver disease about supplement use, emphasizing that many products are marketed ahead of their evidence base.

Frequently Asked Questions

For anyone who wants to go deeper on general liver and digestion support, our digestion and gastrointestinal collection is a good next step.